Table 2

Baseline features of the study cohorts

HCs (n=57)	PsO (n=57)	PsOAr (n=61)	P value PsOAr vs PsO vs HCs	P value PsO vs HCs	P value PsOAr vs HCs	P value PsOAr vs PsO
Baseline data
Age, mean (±SD)	47.91 (±13.03)	50.65 (±16.62)	50.49 (±12.27)	0.44	n.a.	n.a.	n.a.
Female, n (%)	39 (69.64%)	28 (49.12%)	34 (55.74%)	0.08	n.a.	n.a.	n.a.
Smoking, n (%)	8 (14.55%)	17 (29.82%)	5 (8.2%)	0.02	0.14	0.15	0.008
BMI, mean (±SD)	23 (±3.67)	25 (±3.95)	26 (±4.8)	<0.001	0.002	0.001	0.96
Family history of PsA, n (%)	1 (1.75%)	9 (16.07%)	7 (11.48%)	0.02	0.008	0.062	0.59
Diabetes mellitus, n (%)	2 (3.51%)	3 (5.26%)	5 (8.2%)	0.61	n.a.	n.a.	n.a.
Hypertension, n (%)	6 (10.53%)	11 (19.3%)	19 (31.15%)	0.03	0.29	0.007	0.20
Metabolic syndrome, n (%)	4 (7.02%)	4 (7.02%)	11 (18.03%)	0.10	n.a.	n.a.	n.a.
Depression, n (%)	1 (1.75%)	3 (5.26%)	9 (14.75%)	0.03	0.62	0.017	0.13
Patient-reported symptoms and baseline clinical examination
VAS pain (0–10), mean (±SD)	2 (±2)	2 (±2.39)	4 (±2.35)	<0.001	0.97	<0.001	<0.001
HAQ, mean (±SD)	0 (±0.21)	0 (±0.48)	0 (±0.39)	<0.001	0.05	<0.001	<0.001
Tender joints count, mean (±SD)	0.37 (±1.1)	0.49 (±0.98)	2.98 (±4.7)	<0.001	0.14	<0.001	<0.001
Tender enthesis count, mean (±SD)	0.02 (±0.13)	0.09 (±0.34)	0.64 (±1.14)	<0.001	0.17	<0.001	<0.001
PASI, mean (±SD)	n.a.	3.79 (±3.29)	4.34 (±5.65)	n.a.	n.a.	n.a.	0.92
NAPSI, mean (±SD)	n.a.	9.07 (±8.50)	8.48 (±7.95)	n.a.	n.a.	n.a.	0.76

Joints tenderness was evaluated in 68 joints. Tender entheses count was evaluated in six sites of LEI plus bilateral quadriceps patellar insertion, proximal and distal patellar insertion and plantar fascia.
Values in bold signifies p value ≤0.05.
BMI, body mass index; HAQ, Health Assessment Questionnaire; HC, healthy control; LEI, Leeds enthesitis index; n.a., not applicable; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis alone; PsOAr, psoriatic patients with arthralgia; VAS, Visual Analogue Scale.